Sugi Predict

Sugi Predict / Compounds / SCHEMBL3854878

SCHEMBL3854878

SCHEMBL3854878

CCOC(=O)c1c(O)c(-c2ccc(F)cc2)nn(Cc2ccccc2C(F)(F)F)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ KDM4E B2RXH2 7/20 0.41
▸ NR1H2 P55055 3/20 0.41
▸ NR1H3 Q13133 3/20 0.41
▸ NR1I2 O75469 1/20 0.41
▸ NR3C1 P04150 1/20 0.41
▸ PTGS2 P35354 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ PDE4A P27815 2/20 0.39
▸ PDE4B Q07343 2/20 0.39
▸ PDE4C Q08493 2/20 0.39
▸ PDE4D Q08499 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ F2RL3 Q96RI0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3847891 0.92 ALDH1A1 (0.41) ALDH1A1L3MBTL1KDM4EPDE4APDE4B
SCHEMBL3847819 0.87 ALDH1A1 (0.38) ALDH1A1L3MBTL1KDM4EPDE4APDE4B
SCHEMBL3849543 0.87 ALDH1A1 (0.47) ALDH1A1KDM4ENR1H2NR1H3MEN1
SCHEMBL3851454 0.85 ALDH1A1 (0.47) ALDH1A1L3MBTL1KDM4EMEN1HPGD
SCHEMBL3846850 0.83 KDM4E (0.45) ALDH1A1KDM4EGAALMNA
SCHEMBL3850103 0.83 PDE4A (0.52) ALDH1A1KDM4EMEN1HPGDKMT2A
SCHEMBL3857680 0.82 KDM4E (0.43) ALDH1A1L3MBTL1KDM4EMEN1KMT2A
SCHEMBL15536508 0.81 NR1H2 (0.40) ALDH1A1KDM4ENR1H2NR1H3NR1I2
SCHEMBL3848575 0.81 EGLN3 (0.54) RORC
SCHEMBL3853375 0.79 ALDH1A1 (0.48) ALDH1A1KDM4EMEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 — — EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 — — US disclosed
CN-101626685-B N-substituted glycine derivatives: hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2013-03-13 — — CN disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 — — US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN ALDH1A1 564/4885L3MBTL1 2831/4885KDM4E 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.